Evidence map›Paper›PMID 32385519›Full record

ArticleCancer immunology, immunotherapy : CII2020

Aberrant peripheral blood CD4

Mehdi Dehghani, Mehdi Kalani, Hossein Golmoghaddam, Mani Ramzi, Nargess Arandi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mehdi DehghaniHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mehdi KalaniDepartment of Immunology, Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossein GolmoghaddamDepartment of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mani RamziHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nargess ArandiHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. arandin@sums.ac.ir.ORCID http://orcid.org/0000-0001-6489-0979
Shiraz University of Medical Sciences · IR

Funding

Shiraz University of Medical Sciences 95-01-32-12334
6 · The paper itself

Abstract

Little is known about the clinical significance of the peripheral blood CD4

Indexed as

AdultAgedAged, 80 and overCD4 AntigensFemaleForkhead Transcription FactorsHumansInterleukin-2 Receptor alpha SubunitMaleMiddle AgedNeoplasm Recurrence, LocalTh17 CellsT-Lymphocytes, RegulatoryYoung AdultCD4 AntigensForkhead Transcription FactorsFOXP3 protein, humanIL2RA protein, humanInterleukin-2 Receptor alpha SubunitFOXP3LymphomaPrognosisRegulatory T cells (Tregs)T helper 17 (Th-17)

Identifiers

PMID32385519
PMCPMC11027683
OpenAlexW3022834105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.